IRIS
DE ANGELIS, CARMINE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.099
EU - Europa 2.158
NA - Nord America 1.934
SA - Sud America 474
AF - Africa 68
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.738
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.834
SG - Singapore 1.646
RU - Federazione Russa 1.104
CN - Cina 666
IT - Italia 473
BR - Brasile 390
HK - Hong Kong 288
VN - Vietnam 252
DE - Germania 168
NL - Olanda 95
IN - India 83
GB - Regno Unito 67
CA - Canada 53
FI - Finlandia 45
KR - Corea 44
AR - Argentina 41
FR - Francia 37
IE - Irlanda 31
MX - Messico 29
UA - Ucraina 26
CI - Costa d'Avorio 21
ZA - Sudafrica 20
AT - Austria 17
JP - Giappone 17
SE - Svezia 17
ES - Italia 16
PL - Polonia 16
EC - Ecuador 15
PK - Pakistan 15
BD - Bangladesh 14
IQ - Iraq 13
ID - Indonesia 12
LT - Lituania 9
CO - Colombia 8
VE - Venezuela 6
CZ - Repubblica Ceca 5
PY - Paraguay 5
TR - Turchia 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
IL - Israele 4
JM - Giamaica 4
MA - Marocco 4
NP - Nepal 4
SA - Arabia Saudita 4
TN - Tunisia 4
DZ - Algeria 3
LV - Lettonia 3
MY - Malesia 3
RS - Serbia 3
AZ - Azerbaigian 2
BE - Belgio 2
BF - Burkina Faso 2
BO - Bolivia 2
BY - Bielorussia 2
BZ - Belize 2
DK - Danimarca 2
DM - Dominica 2
EG - Egitto 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
MK - Macedonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
PT - Portogallo 2
TW - Taiwan 2
ZM - Zambia 2
AD - Andorra 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BG - Bulgaria 1
BS - Bahamas 1
CH - Svizzera 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HN - Honduras 1
HR - Croazia 1
IR - Iran 1
JO - Giordania 1
KE - Kenya 1
KH - Cambogia 1
KZ - Kazakistan 1
LI - Liechtenstein 1
MC - Monaco 1
MD - Moldavia 1
ME - Montenegro 1
MG - Madagascar 1
MQ - Martinica 1
MR - Mauritania 1
MU - Mauritius 1
MW - Malawi 1
NC - Nuova Caledonia 1
Totale 7.723
Salva come PNG Salva come JPEG
Città #
Singapore 826
Hong Kong 288
Moscow 259
Hefei 252
Chandler 189
Beijing 173
Ashburn 153
Naples 123
Santa Clara 106
Ho Chi Minh City 89
Amsterdam 82
Dallas 79
Millbury 65
Los Angeles 61
Hanoi 51
Lawrence 46
Kochi 44
Seoul 42
Redondo Beach 41
Munich 39
Des Moines 38
Napoli 34
São Paulo 34
Boston 33
Buffalo 31
Dearborn 30
Nuremberg 28
Dong Ket 26
The Dalles 26
New York 25
Milan 23
Wilmington 21
Turku 19
London 18
Montreal 17
Princeton 17
Nanjing 16
Ottawa 16
Seattle 16
Warsaw 16
Denver 14
Haiphong 14
Mexico City 14
Pune 14
Chicago 13
Houston 13
Rio de Janeiro 13
Rome 13
Stockholm 12
Belo Horizonte 11
Kagoya 10
Curitiba 9
Lappeenranta 9
Manchester 9
Salvador 9
Frankfurt am Main 8
Johannesburg 8
Ninh Bình 8
Brasília 7
Dhaka 7
Pomigliano d'Arco 7
Quito 7
Toronto 7
Vienna 7
Atlanta 6
Buenos Aires 6
Casoria 6
Dublin 6
Fairfield 6
Formia 6
Guayaquil 6
Hebei 6
Jacksonville 6
Krefeld 6
Phoenix 6
Porto Alegre 6
Praia Grande 6
Tianjin 6
Biên Hòa 5
Boardman 5
Borgomanero 5
Brooklyn 5
Campobasso 5
Da Nang 5
Düsseldorf 5
Erbil 5
Falkenstein 5
Guangzhou 5
Lahore 5
Orem 5
Piracicaba 5
Poplar 5
Redwood City 5
San Francisco 5
Shanghai 5
Tokyo 5
Wuhan 5
Afragola 4
Asunción 4
Baghdad 4
Totale 3.926
Salva come PNG Salva come JPEG
Nome #
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 149
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 139
Prevalence of Sarcopenia in Women with Breast Cancer 130
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 127
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 121
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 121
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 120
Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy 118
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 118
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 117
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 116
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 115
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 115
Tumor characteristics and prognosis in familial breast cancer 114
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 114
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 111
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis 111
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 109
Breast cancer prognosis in BRCA1/2 mutation carriers: A case control study. 108
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 107
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study 105
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 105
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 104
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 101
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 100
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 100
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance 100
Brca1/2 ngs somatic testing in clinical practice: a short report 100
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories 99
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 99
How SARS-CoV-2 Infection Impacts the Management of Patients with Vulvar Cancer: Experience in a Third-Level Hospital of Southern Italy 99
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type 98
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs 98
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 96
GMO-Gestione Malattie Oncologiche in Regione Campania. 96
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer 95
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 92
Triple-negative breast cancers: Biomarkers and outcomes 91
Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy 91
Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie 89
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis 85
Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer 85
Ribociclib in newly diagnosed hepatitis B infection: A case report 84
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 83
Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study 82
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer 82
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer 82
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer 82
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy 80
Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. 79
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer 79
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance 78
PTK6 regulates growth and survival of endocrine therapyresistant ER+ breast cancer cells 77
Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients 77
Neratinib in HER2-Positive Breast Cancer Patients 76
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer 74
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications 74
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance 72
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer 72
Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a 71
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer 70
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 69
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer 68
Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment 68
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer 65
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. 65
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies 64
Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy 64
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy 64
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 64
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer 63
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer 62
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 60
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study 60
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials 59
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer 59
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. 56
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer 56
HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer 56
Molecular mechanisms of endocrine resistance 55
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study 54
Towards personalized treatment for early stage HER2-positive breast cancer 54
Tamoxifen resistance in breast cancer is regulated by the EZH2–ERa–GREB1 transcriptional axis 53
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance 51
The changing role of ER in endocrine resistance 50
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance 48
Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic 44
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer 43
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models 42
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation 42
Resistance to Anti-HER2 Therapies in Breast Cancer 41
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests 41
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer 40
Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer 38
Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity. 37
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition 32
What medical oncologist residents think about the Italian speciality schools: A survey of the Italian Association of Medical Oncology (AIOM) on educational, clinical and research activities 31
Editorial: Molecular predictive pathology in gynecologic malignancies 31
Totale 7.931
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.520
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.520
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021115 0 0 0 0 0 13 13 6 30 9 12 32
2021/2022410 7 1 61 1 6 14 11 14 37 32 95 131
2022/2023568 66 36 21 30 57 56 15 52 69 96 53 17
2023/2024478 15 70 59 28 22 53 10 41 17 19 97 47
2024/20252.807 136 167 7 71 58 145 341 173 184 373 922 230
2025/20263.210 537 480 587 568 894 144 0 0 0 0 0 0
Totale 7.931